IDXX
Idexx Laboratories Inc
$670.71-3.99%
Setup
①BreakoutBreakout
Buy Zone
$536.84-$563.68
Sector
Diagnostics & Research
Industry
Diagnostics & Research
41
Recommendation
Extended
Avoid①
Setup may be valid but price is no longer in a clean buy zone.
IDXX chart
Loading chart…
ADX
Weak or Absent10.0Long Term
Range →Intermediate Term
Range →Short Term
Range →Overall Quality41
RS Rating
26
relative strength
Fundamentals
75
Strong fund-Q
Volume Demand
68
+53% vs avg
Technical Setup
50
4/8 checks
Industry/Theme
91
Diagnostics & Research
Trade Plan
Extended
Entry
$536.84
Entry Zone
$536.84-$563.68
Stop / Risk
$493.89
RS Rating
26
Volume confirmed
No
Targets
$644.21 / $671.05
Breakout · IBD Setup
2 ✓ 6 ✗
Entry $536.84–$563.68Stop $493.89Target $644.21 / $671.05
Market regimeRange
Quality41
RS Rating26
Above 50-MA+23.26%
Above 200-MA+17.23%
VolumeWeak
In Buy ZoneNo
Not extendedExtended
Invalidation · Close below stop
How this came together
41
MarketRange
Setup①BreakoutBreakout
ConfidenceMedium · 476 trades · 38% win · +0.30R
Fund-Q75 · Strong
StatusAvoid①
Stock Data
52-Week Range501 – 770
Price % Chg YTD-0.86%
Price % Chg 4wk32.38%
50-Day Avg Vol0.6 Mil
P/E Ratio38.7
Market Cap$43B
SectorHealthcare
IndustryDiagnostics & Research
Company Fundamentals
EPS % Chg (Qtr)17.55%
Sales % Chg (Qtr)9.66%
EPS Growth 5y14.28%
Sales Growth 5y9.72%
Annual ROE74.21%
Gross Margin62.53%
Operating Margin32.12%
Net Margin25.03%
Debt / Equity0.68
Setup levels
Current price
$670.71
Pivot
$536.84
Distance to buy
-12.9%
52-week range
500.6-769.96
Trigger evidence
W double-bottom base
broke the middle peak 536.84 on volume ≥1.4×
Pattern levels: pivot 536.84
Financial health checks
5/5
Return on equity above 15%
ROE 74.21%
Net margin above 10%
Net margin 25.03%
EPS growing quarter on quarter
EPS q/q 17.55%
Sales growing quarter on quarter
Sales q/q 9.66%
Debt to equity below 1.0
D/E 0.68
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE74.21%
vs sector +51.6%
Net margin25.03%
vs sector +7.4%
Gross margin62.53%
vs sector -4.6%
EPS growth q/q17.55%
vs sector +10.0%
Sales growth q/q9.66%
vs sector -9.1%
Debt / equity0.68
vs sector +0.03
Business quality
75
GradeStrong
EPS rating50
P/E38.7
Market cap$43B
IndustryDiagnostics & Research
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Fail
In Kaufzone
Fail
Nicht überextended
Fail
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-11-05
Trigger date
—
Days on list
1
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.